-
Study aim
-
Evaluation of the effect of adding Dexmedetomidine to Propofol in pediatric Electroconvulsive therapy
-
Design
-
Clinical trial with control group, with parallel groups, double-blind, randomized, phase 3 on 70 patients. Lottery was used for randomization.
-
Settings and conduct
-
This study is a randomized, double-blind clinical trial that will be performed on children who are candidates for electroconvulsive therapy at Al-Zahra Hospital in Isfahan. Before the arrival of patients, their parents will be informed about the study and if they are satisfied, they will be prepared and monitored for the intervention. Patients are randomly distributed in two groups and each group receives the relevant intervention after propofol injection. The clinical caregiver is different from the person injecting the drug and is unaware of the type of intervention.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: 4 to 16 years old, ECT candidate, ASA class I and II anesthesia
Exclusion criteria: History of seizures, Heart failure, Kidney failure, Liver failure, Respiratory failure, History of allergy to the studied drugs, Addiction to psychotropic substances, History of egg allergy
-
Intervention groups
-
Intervention group A: In this group, after injecting propofol, patients are injected with 0.5 mg of dexmedetomidine per kg of body weight.
Intervention group B: In this group, after injection of propofol, patients are injected with 0.5 ml of normal saline.
-
Main outcome variables
-
Heart rate changes; Changes in blood pressure